CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Herantis is developing a new pharmaceutical called HER-096 aimed at treating Parkinson's disease by addressing its underlying pathology. This innovative approach seeks to provide a disease-modifying therapy that could significantly improve the quality of life for millions affected by this neurodegenerative disorder.
Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, whereof 1.2 million in the EU.
This chronic disabling disease affects the central nervous system, causing severe motor and non-motor symptoms.
The high disease burden for patients and their family also comes with a big price tag for society, which is expected to increase dramatically with an ageing population.
In EU the annual cost is 14 B€ currently.
The causes of PD are unknown and ther…
HERANTIS PHARMA OYJ
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
